Abstract
Drug-eluting stents have revolutionised the treatment of coronary artery disease, delivering reduced rates of treatment failure across the range of disease presentations and allowing for the expansion of catheter-based revascularisation to patients with complex disease patterns.1 Nevertheless, the efficacy of these devices in preventing restenosis occurs at the expense of a delay in healing of the stented artery, which underlies, among other things, a small but relevant increase in late adverse events such as stent thromboses, at least with early-generation devices.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
